GlassScriptPhysician profile
Randall Brian Evans
NPI 1124096623
$1,094.21
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.63 · 2020: $412 · 2021: $586 · 2022: $78.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $267.37 | 2020-2021 | |
| Glaxosmithkline, LLC. | $154.56 | 2020-2021 | |
| Mylan Specialty L.P. | $103.74 | 2021-2022 | |
| Grifols USA, LLC | $96.74 | 2021 | |
| Insmed, INC. | $88.04 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $68.18 | 2020-2021 | |
| Harmony Biosciences LLC | $51.02 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.47 | 2020-2021 | |
| Palette Life Sciences, INC. | $40.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $40.22 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $30.34 | 2020-2021 | |
| Philips North America LLC | $20.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.46 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.46 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.37 | 2021 | |
| Advanced Respiratory, INC | $12.67 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.